Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent Signs Commercial Mfg. Agreement with US WorldMeds | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Catalent Signs Commercial Mfg. Agreement with US WorldMeds

Will manufacture lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.

US WorldMeds has the rights to commercialize lofexidine in the U.S., which is currently approved as Britlofex in the UK. Catalent and US WorldMeds have worked together to successfully tech transfer the manufacturing from a facility overseas to Catalent’s Winchester, KY, facility, where they have produced registration batches to support US WorldMeds’ New Drug Application to the U.S. FDA and the anticipated commercial launch.

Lofexidine received Fast Track designation by the FDA, a process designed to expedite the review of drugs that treat serious conditions and address an unmet medical need. If approved, lofexidine would be the first non-narcotic and non-addictive medication in the U.S. for treatment of symptoms associated with opioid withdrawal.

“Symptoms of opioid withdrawal can be a significant barrier in seeking help and breaking the cycle of dependence and addiction,” said Jonathan Arnold, ‎vice president and general manager, drug delivery solutions, Catalent. “We are excited to join forces with US WorldMeds to bring a potential new treatment option to a major health issue spanning the nation.”

Catalent’s Winchester facility has more than 20 years’ experience in product development, technology transfer and commercial manufacturing. The site has produced over three billion tablets and capsules annually and launched more than 100 new products into the market since its inception.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics